ArticleOncogene2005
Exclusion of RUNX3 as a tumour-suppressor gene in early-onset gastric carcinomas.
Article in Oncogene, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Association between RUNX3 promoter methylation and gastric cancer: a meta-analysis.BMC gastroenterology · 2011Pooled it
- Article
- Oncosuppressive Role of RUNX3 in Human Astrocytomas.Journal of oncology · 2019Article
- Truncated forms of RUNX3 Unlike Full Length Protein Alter Cell Proliferation in a TGF-β Context Dependent Manner.Iranian journal of pharmaceutical research : IJPR · 2017Article
- Molecular alterations in gastric cancer with special reference to the early-onset subtype.World journal of gastroenterology · 2016Review
- Runt-related transcription factor 3: single nucleotide polymorphism rs760805, gene expression, and methylation status in Helicobacter pylori -infected patients for determination of gastric cancer risk.Journal of gastrointestinal cancer · 2013Article
- Antitumor activity of cell-permeable RUNX3 protein in gastric cancer cells.Clinical cancer research : an official journal of the American Association for Cancer Research · 2013Article
- Absence of Runx3 expression in normal gastrointestinal epithelium calls into question its tumour suppressor function.EMBO molecular medicine · 2011Article
- Low frequency of HER2 amplification and overexpression in early onset gastric cancer.Cellular oncology (Dordrecht, Netherlands) · 2011Article
- The role of EZH2 and DNA methylation in the silencing of the tumour suppressor RUNX3 in colorectal cancer.Carcinogenesis · 2010Article
- Early-onset gastric cancer: Learning lessons from the young.World journal of gastrointestinal oncology · 2010Article
- Article
- Methylation of the Tumor Suppressor Gene RUNX3 in Human Gastric Carcinoma.Gut and liver · 2008Article
- IL-1B -31T>C promoter polymorphism is associated with gastric stump cancer but not with early onset or conventional gastric cancers.Virchows Archiv : an international journal of pathology · 2008Article
- Downregulation of the RUNX3 gene by promoter hypermethylation and hemizygous deletion in breast cancer.Journal of Korean medical science · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent studies claim a critical role for RUNX3 in gastric epithelial homeostasis. However, conflicting results exist regarding RUNX3 expression in the stomach and its potential role as a tumour-suppressor gene (TSG) in gastric carcinogenesis. Our aim was to evaluate the role of RUNX3 in early-onset gastric carcinomas (EOGCs). We analysed 41 EOGCs for RUNX3 aberrations using loss of heterozygosity (LOH), fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) analyses. LOH of markers flanking RUNX3 was relatively common, indicating that loss of the gene may play a role in gastric carcinogenesis. However, FISH analysis of selected cases and a panel of 14 gastric carcinoma-derived cell lines showed widespread presence of multiple copies of centromere 1. While RUNX3 copy numbers were generally equal to or fewer than those of centromere 1, at least two copies were present in almost all cells analysed. Accordingly, a subpopulation of tumour cells in 12/37 cases showed RUNX3 protein expression. However, expression was not detected in the adjacent nontumorous mucosa of any case. Together, these observations indicate that chromosome 1 aberrations occur frequently in EOGCs and are reflected in the LOH and IHC patterns found. Our findings refute a role for RUNX3 as a TSG in EOGCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.